🚀 VC round data is live in beta, check it out!
Baxter International Valuation Multiples
Discover revenue and EBITDA valuation multiples for Baxter International and similar public comparables like Mankind Pharma, Olympus, Samsung Bioepis, Zydus Lifesciences and more.
Baxter International Overview
About Baxter International
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
Founded
1931
HQ
Employees
37.5K
Website
Financials (LTM)
EV
$18B
Baxter International Financials
Baxter International reported last 12-month revenue of $11B and EBITDA of $2B.
In the same LTM period, Baxter International generated $4B in gross profit, $2B in EBITDA, and $1B in net income.
Revenue (LTM)
Baxter International P&L
In the most recent fiscal year, Baxter International reported revenue of $11B and EBITDA of $2B.
Baxter International expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $11B | XXX | $11B | XXX | XXX | XXX |
| Gross Profit | $4B | XXX | $3B | XXX | XXX | XXX |
| Gross Margin | 38% | XXX | 30% | XXX | XXX | XXX |
| EBITDA | $2B | XXX | $2B | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 20% | XXX | XXX | XXX |
| EBIT Margin | 14% | XXX | 14% | XXX | XXX | XXX |
| Net Profit | $1B | XXX | $1B | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | — | — | $8B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Baxter International Stock Performance
Baxter International has current market cap of $10B, and enterprise value of $18B.
Market Cap Evolution
Baxter International's stock price is $19.69.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $18B | $10B | 0.0% | XXX | XXX | XXX | $2.21 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBaxter International Valuation Multiples
Baxter International trades at 1.6x EV/Revenue multiple, and 8.2x EV/EBITDA.
EV / Revenue (LTM)
Baxter International Financial Valuation Multiples
As of April 5, 2026, Baxter International has market cap of $10B and EV of $18B.
Equity research analysts estimate Baxter International's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Baxter International has a P/E ratio of 9.2x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $10B | XXX | $10B | XXX | XXX | XXX |
| EV (current) | $18B | XXX | $18B | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | 8.2x | XXX | 8.0x | XXX | XXX | XXX |
| EV/EBIT | 11.4x | XXX | 11.3x | XXX | XXX | XXX |
| EV/Gross Profit | 4.2x | XXX | 5.3x | XXX | XXX | XXX |
| P/E | 9.2x | XXX | 8.9x | XXX | XXX | XXX |
| EV/FCF | 30.0x | XXX | 40.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Baxter International Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Baxter International Margins & Growth Rates
Baxter International's revenue in the last 12 month grew by 1%.
Baxter International's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Baxter International's rule of 40 is 19% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Baxter International's rule of X is 21% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Baxter International Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1% | XXX | 1% | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Growth | (6%) | XXX | (8%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 19% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 21% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5% | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 28% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Baxter International Public Comps
See public comps and valuation multiples for other Medical Devices and Medical Supplies comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Mankind Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Olympus | XXX | XXX | XXX | XXX | XXX | XXX |
| Samsung Bioepis | XXX | XXX | XXX | XXX | XXX | XXX |
| Zydus Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Madrigal Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Baxter International M&A Activity
Baxter International acquired XXX companies to date.
Last acquisition by Baxter International was on XXXXXXXX, XXXXX. Baxter International acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Baxter International
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBaxter International Investment Activity
Baxter International invested in XXX companies to date.
Baxter International made its latest investment on XXXXXXXX, XXXXX. Baxter International invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Baxter International
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Baxter International
| When was Baxter International founded? | Baxter International was founded in 1931. |
| Where is Baxter International headquartered? | Baxter International is headquartered in United States. |
| How many employees does Baxter International have? | As of today, Baxter International has over 37K employees. |
| Who is the CEO of Baxter International? | Baxter International's CEO is Andrew P. Hider. |
| Is Baxter International publicly listed? | Yes, Baxter International is a public company listed on NYSE. |
| What is the stock symbol of Baxter International? | Baxter International trades under BAX ticker. |
| When did Baxter International go public? | Baxter International went public in 1961. |
| Who are competitors of Baxter International? | Baxter International main competitors are Mankind Pharma, Olympus, Samsung Bioepis, Zydus Lifesciences. |
| What is the current market cap of Baxter International? | Baxter International's current market cap is $10B. |
| What is the current revenue of Baxter International? | Baxter International's last 12 months revenue is $11B. |
| What is the current revenue growth of Baxter International? | Baxter International revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of Baxter International? | Current revenue multiple of Baxter International is 1.6x. |
| Is Baxter International profitable? | Yes, Baxter International is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Baxter International? | Baxter International's last 12 months EBITDA is $2B. |
| What is Baxter International's EBITDA margin? | Baxter International's last 12 months EBITDA margin is 20%. |
| What is the current EV/EBITDA multiple of Baxter International? | Current EBITDA multiple of Baxter International is 8.2x. |
| What is the current FCF of Baxter International? | Baxter International's last 12 months FCF is $599M. |
| What is Baxter International's FCF margin? | Baxter International's last 12 months FCF margin is 5%. |
| What is the current EV/FCF multiple of Baxter International? | Current FCF multiple of Baxter International is 30.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.